Trial Number

100-20

Age range

22 years and under

Gender

Male or Female

Enrolling Patients

Yes

Survival in childhood AML has plateaued despite maximally toxic standard therapy. This study, AAML1831, will evaluate two strategic objectives to improve outcomes and reduce toxicities: 1) continue to build a therapeutic backbone for all patients that improves survival through enhanced efficacy and reduced anthracycline-associated toxicities, 2) introduce target-specific therapies that improve survival without increased toxicity. AAML1831 is a randomized Phase 3 trial that will compare efficacy of CPX-351 (a liposomal preparation of daunorubicin and cytarabine) during Induction 1 and Induction 2 versus standard chemotherapy for children with de novo, non FLT3-mutant AML. This trial incorporates important lessons learned from prior COG Phase 3 studies.

Principal Investigator

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.